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Abstract: Existing data on COPD prevalence are limited or totally lacking in many regions 
of Europe. The geographic information system inverse distance weighted (IDW) interpolation 
technique has proved to be an effective tool in spatial distribution estimation of epidemiological 
variables, when real data are few and widely separated. Therefore, in order to represent carto-
graphically the prevalence of COPD in Europe, an IDW interpolation mapping was performed. 
The point prevalence data provided by 62 studies from 19 countries (21 from 5 Northern European 
countries, 11 from 3 Western European countries, 14 from 5 Central European countries, and 
16 from 6 Southern European countries) were identified using validated spirometric criteria. 
Despite the lack of data in many areas (including all regions of the eastern part of the continent), 
the IDW mapping predicted the COPD prevalence in the whole territory, even in extensive 
areas lacking real data. Although the quality of the data obtained from some studies may have 
some limitations related to different confounding factors, this methodology may be a suitable 
tool for obtaining epidemiological estimates that can enable us to better address this major 
public health problem.
Keywords: epidemiology, geographic information system, GIS, Geographic Resources Analysis 
Support System 
Introduction
COPD is a large, growing public health problem. According to the World Health 
Organization, its expected burden will increase in the coming decades, mostly due to 
continued exposure to risk factors, population growth and aging, to become the third 
leading cause of death by 2030.1 
Despite being a major health problem, existing data on COPD prevalence are lim-
ited in many countries, and universally high COPD underdiagnosis2 or misdiagnosis3 
deprives patients and health authorities of the implementation of adequate preventive 
and therapeutic measures, in order to avoid its potential serious effects and high costs.4 
In fact, of the 50 sovereign European countries, only 19 (38%) of them have available 
reliable data on COPD prevalence.5 
The geographic information system (GIS) is considered a useful tool for reporting 
the distribution of health-related states, in particular diseases.6,7 Specifically, the 
GIS inverse distance weighting (IDW) interpolation (or spatial analysis) technique 
(an informatics mathematical approach of manipulating spatial information to extract 
new information and meaning from the original data, using points with known values 
to estimate values at other unknown points) has proved to be an effective tool in spatial 
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distribution estimation of epidemiological variables, when 
real data are few and widely separated, as might be the case 
with the COPD prevalence in Europe.8–10 
The objective of the present study was to apply the IDW 
mapping to integrate the existing data from different European 
areas, in order to represent cartographically the mean percent-
age of the population affected by COPD in each geographi-
cal region of the entire continent, both in studied areas with 
known data and in many other areas in which no studies have 
been conducted and consequently with blank data. 
Methods
source of epidemiological studies for 
COPD prevalence
The vast majority of the data entered in the database used 
in the IDW interpolation software were taken from the 
systematic review and meta-analysis recently published by 
Adeloye et al on the prevalence of COPD across the world 
from January 1990 to December 2014, based on a confirmed 
diagnosis of COPD with different formally acknowledged 
spirometric criteria.5 For the current study, only the variables 
referring to the place of origin of the samples and the mean 
COPD prevalence (in percent) of the samples composed 
of subjects aged $40 years were used.11–63 To the initially 
selected 61 studies, a later one on the prevalence of COPD, 
as defined by the Global Initiative for Obstructive Lung 
Disease (GOLD), in a representative sample of northeastern 
Italy general population was added.64 
The application of an age selection criterion of $40 years 
excluded, from the present study, an international study that 
included young subjects from several cities in Europe aged 
between 20 and 44 years,65 2 studies performed in 12 Russian 
regions,66,67 and another study of the Turkish region of Elazig 
all of them carried out in subjects from the age of 18.68
In addition, to facilitate visual comparisons between 
Europe and the neighboring regions of Asia and Africa, the 
available COPD prevalence data from several Middle East 
and North Africa regions were also included.69–77
IDW multivariate interpolation method
To elaborate colored geographical maps of COPD preva-
lence, an IDW interpolation process was started through the 
freely available software QGIS 18.9 in order to link it with 
the 7.3 64-bit wxPython 3 Geographic Resources Analysis 
Support System (GRASS). 
Then, the geographical longitude and latitude coordinates 
of the different places were automatically obtained for each 
point by translating the location of the place of origin of the 
samples included. The translation was made through the 
Google Maps application programming interface using the 
web page of GPS Visualizer (Carleton University Library, 
Ottawa, ON, Canada).
Then, these geographical coordinates were imported into 
the database and then exported to a “csv” (comma separated 
value) text file, which was opened and visualized in QGIS. 
A shape file containing the contours of all world countries 
was also loaded.
Finally, the interpolation process was carried out by 
applying the “v.surf.idw” library included in the GRASS GIS 
version 7, another free and open source GIS software suite 
used for geospatial data management and analysis, spatial 
modeling, image processing, graphics and maps production, 
and visualization.
The v.surf.idw library provided surface interpolation from 
vector point data by filling out a raster matrix with interpo-
lated values generated from a set of irregularly spaced data 
points, using numerical approximation (weighted averaging) 
techniques. The interpolated value of a cell was determined 
by the values of the nearby data points and the distance of 
the cell from those input points. 
An implementation of an IDW technique, as defined by 
Shepard,7 is as follows: the way to find an interpolated value u 
at a given (arbitrary) point x based on N known samples 
u
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The “N known samples” is the N closest ones to the 
interpolation point. In our study, the usual N value of 4 
(N=4) was chosen. This means that a sample point takes the 
4 closest pixel centers and linearly interpolates their color 
values according to their distance from the sample point; p is 
called the power parameter, which has a default value of 2, 
which was the value used in this study.
To express the range of values in the maps, a progres-
sive gradient (low–high) range scale of 10 colors, creating a 
diverging low–mid–high color gradient, with dark blue tones 
representing the lowest values, yellow and green representing 
the intermediate ones, and brown and dark red representing 
the highest ones, was used. 
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geographical regions of europe
Although there is not a universally accepted definition of the 
boundaries and countries of the European regions, to facilitate 
the description of findings, we used a simple and conventional 
classification of the regions of Europe into 5 major subre-
gions, namely Northern Europe, Western Europe, Central 
Europe, Southern Europe, and Eastern Europe.79
Northern Europe consists approximately of the Europe 
regions above the 52nd parallel north, and in this geographical 
area, the following countries have been included for this 
study: Iceland, Denmark, Norway, Sweden, Finland, Estonia, 
Latvia, and Lithuania. 
In Western Europe, the following countries have been 
included: the Netherlands, Belgium, Luxembourg, France, 
Ireland, and UK. 
In Central Europe, the following countries have been 
included: Germany, Austria, Poland, Slovakia, Czech 
Republic, Hungary, Slovenia, and Switzerland.
In Southern Europe, the following countries have been 
included: Spain, Portugal, Italy, Greece, Malta, Cyprus, 
and Turkey.
Although there is no consensus on the precise area cov-
ered by Eastern Europe, because the term has a wide range 
of geopolitical, geographical, cultural, and socioeconomic 
connotations, the following countries have been included 
in this region: the Balkan Peninsula countries (Albania, 
Croatia, Bosnia and Herzegovina, Montenegro, Serbia, and 
Macedonia), Romania, Moldova, Bulgaria, Ukraine, Belarus, 
and European Russia.
statistical analysis
Descriptive statistics were used to summarize study sites. Quan-
titative variables were expressed as mean and SD, 95% CI for 
the mean, and range, and they were analyzed using the analysis 
of variance. A p,0.05 was considered statistically significant. 
Statistical calculations were performed using the analytical 
software SPSS 19 (IBM Corp., Armonk, NY, USA).
Results
The cohorts
A total of 62 studies from 19 countries (21 from 5 Northern 
European countries, 11 from 3 Western European countries, 
14 from 5 Central European countries, and 16 from 6 
Southern European countries) were selected (Tables 1–4). 
As mentioned previously, no prevalence data were available 
for any of the 12 countries from Eastern Europe.
Numbers of point estimates by individual coun-
tries (from high to less) were as follows: Sweden, 8; 
United Kingdom, 7; Norway, 5; Finland, Germany, 
and Turkey, 4 each; the Netherlands, Austria, Poland, 
Portugal, and Spain, 3 each; Italy and Greece, 2; 
and other remaining countries, 1.
Table 1 Mean prevalence of COPD in 21 studies from 5 northern europe countries
Country Source of 
samples
Setting Age 
(years)
Diagnosis 
criteria
COPD 
prevalence (%)
Study
Denmark Copenhagen Urban 63 gOlD 17 Fabricius et al11
Denmark Copenhagen Urban 50 gOlD 25 Maio et al12
Denmark aarhus and aalborg Mixed 65 gOlD 12 hansen et al13
Finland helsinki Urban 49 gOlD/lln 6 Kainu et al14
Finland lahti rural 48 gOlD 9 Jyrki-Tapani et al15
Finland lieto rural 73 FeV1/FVC #65% 8 Isoaho et al
16
Finland Ylöjärvi Mixed 55 gOlD 5 Kanervisto et al17
Iceland reykjavik Urban 57 gOlD 18 Benediktsdóttir et al18
norway hordaland county Mixed 55 gOlD 9 Waatevik et al19
norway Bergen municipality Mixed 61 gOlD 9 hvidsten et al20
norway Bergen Urban 58 gOlD 19 Buist et al21
norway hordaland county Mixed 42 gOlD 5 Bakke et al22
norway Bergen municipality Mixed 46 gOlD 5 Johannessen et al23
sweden Uppsala Urban 59 lln 10 Danielsson et al24
sweden lulea rural 61 gOlD 14 lindberg et al25
sweden lulea rural 49 gOlD 14 lindberg et al26
sweden norrbotten county rural 61 gOlD 11 lindberg et al26
sweden northern sweden rural 50 BTs 10 lindström et al27
sweden stockholm Urban 53 gOlD 20 Maio et al12
sweden Värmland county rural 45 BTs 2 hasselgren et al28
sweden Örebro Mixed 49 aTs 11 larsson29
Note: The numerical values of age and prevalence have been rounded. 
Abbreviations: aTs, american Thoracic society; BTs, British Thoracic society; gOlD, global Initiative for Chronic Obstructive lung Disease; lln, lower limit of 
normal.
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Accordingly, a total of 329,413 subjects from the 
4 regions of Europe with published data were studied; they 
were distributed as follows: 39,836 in Northern Europe; 
229,083 in Western Europe; 25,553 in Central Europe; and 
34,941 in Southern Europe. 
The size of the selected samples was significantly dif-
ferent in the 4 European regions, with a mean (minimum 
and maximal values in parentheses) of 1,897 (548–6,525) 
subjects in Northern Europe; 20,751 (246–185,325) in 
Western Europe; 1,825 (432–6,126) in Central Europe; and 
2,329 (500–9,061) in Southern Europe. 
Most of the studies were conducted in isolated cities 
or localized regions of a particular country, while only a 
few were carried out on samples representative of the adult 
general population of an entire country, such as those per-
formed in the Netherlands,33 UK,39 Switzerland,50 Portugal,52 
Spain,54,55 and Cyprus.60 
According to the study base of the samples, 23 of them 
were classified as urban (7 from Northern Europe, 4 from 
Western Europe, 7 from Central Europe, and 5 from Southern 
Europe), 9 (6 from Northern Europe, 1 from Central Europe, 
and 2 from Southern Europe) were classified as rural, and 
the remaining 30 were catalogued as mixed. 
The mean age of the subjects from the 62 selected samples 
was 55.9 years (SD =6.1), without significant differences 
between regions (Table 5).
In 80% of the studies, the diagnosis of COPD was 
made by using the GOLD spirometric criteria of the 
Table 2 Mean prevalence of COPD in 11 studies from 3 Western europe countries
Country Source of samples Setting Age 
(years)
Diagnosis 
criteria
COPD 
prevalence (%)
Study
France Paris Urban 63 gOlD 7 roche et al30
the netherlands Maastricht Urban 59 gOlD/lln 19 Vanfleteren et al31
the netherlands rotterdam Urban 69 gOlD 12 van Durme et al32
the netherlands general population 
of the whole country 
Mixed 58 gOlD 4 afonso et al33
UK Birmingham Mixed 58 gOlD 9 Jordan et al34
UK ashington Urban 59 gOlD 25 Melville et al35
UK greater Belfast area Mixed 55 aTs 7 Murtagh et al36
UK glasgow Urban 51 gOlD 24 Maio et al12
UK Barton-upon-humber Mixed 68 gOlD 10 Dickinson et al37
UK Manchester Mixed 64 gOlD 26 renwick and Connolly38
UK general population 
of the whole country
Mixed 56 gOlD 13 shahab et al39
Note: The numerical values of age and prevalence have been rounded. 
Abbreviations: aTs, american Thoracic society; gOlD, global Initiative for Chronic Obstructive lung Disease; lln, lower limit of normal.
Table 3 Mean prevalence of COPD in 14 studies from 5 Central europe countries
Country Source of samples Setting Age 
(years)
Diagnosis 
criteria
COPD 
prevalence (%)
Study
austria salzburg Mixed 58 gOlD 17 Weiss et al40
austria salzburg Urban 59 gOlD 26 schirnhofer et al41
austria Vienna Urban 56 gOlD 20 Maio et al12
germany hannover Mixed 58 gOlD 13 geldmacher et al42
germany Dusseldorf Urban 59 gOlD 9 gingter et al43
germany Munich Urban 59 gOlD 21 Maio et al12
germany Berlin Urban 41 gOlD 16 Maio et al12
Poland Warsaw Mixed 57 lln 9 Bednarek et al44
Poland Malopolska province Mixed 56 gOlD 22 nizankowska-Mogilnicka et al45
Poland Warsaw Urban 49 gOlD 11 Plywaczewski et al46
Poland lublin region rural 50 gOlD 11 Paprzycki et al47
Poland Bytom Mixed 59 gOlD 6 siatkowska et al48
slovenia sezana (Carso) Urban 56 gOlD 10 grzetic-romcevic et al49
switzerland general population 
of the whole country
Mixed 54 gOlD 5 Bridevaux et al50
Note: The numerical values of age and prevalence have been rounded. 
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; lln, lower limit of normal.
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postbronchodilator (post-BD) fixed ratio FEV
1
/FVC ,0.70; 
in the remaining 12 studies, other spirometric criteria (not 
post-BD) endorsed by different scientific societies were 
used, such as the lower limit of normal, the British Thoracic 
Society, the American Thoracic Society, and European 
Respiratory Society criteria.
COPD prevalence
The global mean prevalence of COPD (expressed in percent) 
was 12.38 (SD =6.2) without significant differences among 
the 4 European regions with available data (Table 6).
The highest values of prevalence were found in 2 samples 
from the cities of Manchester and Salzburg (26% each), 
followed by those of Ashington and Copenhagen (with 25% 
each); the COPD subjects from Glasgow, the Po Delta area 
of Italy, and the southern Poland region of Malopolska (with 
24%, 23%, and 22%, respectively); and the COPD subjects 
from the metropolitan areas of Stockholm and Vienna (with 
20% each). 
Prevalence rates between $15% and #20% were found 
in the cities of Bergen and Maastricht and in the Turkish 
province of Adana (all with 19%), in the metropolitan 
areas of Reykjavik and Thessaly (both 18%), and in Berlin 
(with 16%).
Prevalence ranges between $10% and #15% were 
found in a sample from Luleå (in the northernmost county 
of Sweden) with 14%, followed by 2 samples from Barton-
upon-Humber (England) and Hannover (Germany) both 
with 13% and the patients’ samples from the Danish cities 
of Aarhus and Aalborg and the Dutch city of Rotterdam 
(with 12%). Prevalence value of 11% was found in Warsaw, 
in the Polish region of Lublin, and in the Swedish counties 
of Norrbotten and Örebro. Prevalence values slightly .10% 
were found in Slovenia, Spain, and Portugal and in the 
general population of the UK.
In practically all of the remaining places with available 
data, prevalence ranged from 5 to ,10%. Anecdotally, a 
young rural cohort, with a mean age of 45 years, from the 
Table 4 Mean prevalence of COPD in 15 studies from 6 southern europe countries
Country Source of samples Setting Age 
(years)
Diagnosis 
criteria
COPD 
prevalence (%)
Study
Portugal lisbon Urban 63 gOlD 14 Bárbara et al51
Portugal general population of the whole country Mixed 56 gOlD 9 Cardoso et al52
Portugal Porto Urban 58 gOlD 11 Mascarenhas et al53
spain Multicenter study on 11 cities Mixed 57 gOlD 10 Miravitlles et al54
spain Multicenter study on 7 geographical areas Mixed 54 ers 9 Peña et al55
spain Canary Islands Urban 55 gOlD 7 Cabrera lópez et al56
Italy Po Delta area rural 57 gOlD 23 Viegi et al57
Italy Verona Mixed 56 gOlD/lln 12 guerriero et al64
greece exochi, Thessaloniki Mixed 52 gOlD 6 sichletidis et al58
greece Thessaly region rural 54 gOlD 18 Minas et al59
Cyprus general population of the whole island Mixed 54 gOlD 5 Zachariades et al60
Turkey Kocaeli city Urban 56 gOlD 13 arslan et al61
Turkey erzurum rural 55 gOlD 5 erdogan et al62
Turkey Malatya region Mixed 47 aTs/ers 7 gunen et al63
Turkey adana Mixed 54 gOlD 19 Buist et al21
Note: The numerical values of age and prevalence have been rounded. 
Abbreviations: aTs, american Thoracic society; ers, european respiratory society; gOlD, global Initiative for Chronic Obstructive lung Disease; lln, lower limit of 
normal.
Table 5 ages of selected samples, descriptive statistics
Region Number of 
studies
Mean 
(years)
SD 95% CI 
(lower limit)
95% CI 
(upper limit)
Minimum Maximum
northern europe 21 54.8 7.7 51.3 58.3 42.0 73.0
Western europe 11 60.3 5.6 56.5 64.0 50.9 69.5
Central europe 14 55.0 5.2 52.0 58.1 40.1 59.5
southern europe 16 55.2 3.2 53.5 56.9 47.5 62.8
global 62 55.9 6.1 54.4 57.5 40.8 73.0
Note: Interregions: p=0.071, no significant differences (ANOVA).
Abbreviation: anOVa, analysis of variance.
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Swedish county of Värmland showed the lowest prevalence 
of COPD in Europe, with a percentage slightly .2%. 
IDW interpolation maps
In the IDW interpolation map of Figure 1, the prevalence 
rates of COPD of all European countries are represented by 
a red–blue scale. Black spots indicate the places of origin 
of the samples. 
In a simplified way, since there is no exact equivalence 
between the qualitative data provided by the color scale and 
the quantitative ones provided by the numerical values, it 
can be interpreted with reasonable certainty that red tones 
represent the maximum values .20%; brown and orange 
colors symbolize high but lower values of ~15%–20%; 
shades of yellow and green tones represent intermediate 
values of ~10%–15%; and blue tones represent minimal 
values of 0%–5%. 
The greatest numbers of black spots are located in the 
Iberian Peninsula, Great Britain, Central Europe, and the 
coastal regions bordering the North and the Baltic Seas. 
In contrast, spots are in general scattered and scanty in most 
of the remaining parts of the continent and absolutely absent 
in the Mediterranean islands of Corsica, Sardinia, Sicily 
and Greek islands, southern Italy, Balkan Peninsula, and 
regions belonging to Eastern Europe. 
Some black spots can also be seen in some nearby 
countries of North Africa and Middle East (for guidance).
In Figure 2, the numerical values of the corresponding 
prevalence rates have been added. The numerical values 
appear with a decimal and are the same reproduced (rounded) 
in Tables 1–4. 
In the map of Figure 3, both black spots and numerical 
figures have been removed to allow a clearer view of the 
colors with which the different regions were colored. 
Table 6 COPD prevalence in europe, descriptive statistics
Region Number of 
studies
Mean 
prevalence (%)
SD 95% CI 
(lower limit)
95% CI 
(upper limit)
Minimum Maximum
northern europe 21 11.5 5.9 8.8 14.1 2.1 25.4
Western europe 11 14.2 8.0 8.8 19.6 3.9 26.4
Central europe 14 14.1 6.5 10.4 17.9 5.0 26.1
southern europe 16 10.8 5.6 7.8 13.8 4.9 23.4
global 62 12.4 6.2 10.8 14.0 2.1 26.4
Note: Interregions: p=0.3460, no significant differences (ANOVA).
Abbreviation: anOVa, analysis of variance.
,':Q S &23'PHDQSUHYDOHQFH

Figure 1 COPD mean prevalence in europe.
Notes: In this IDW interpolation map, the COPD prevalence is represented by a red–blue scale. Black spots indicate the places of origin of the data obtained from 
62 selected studies. some black spots are also shown in some nearby countries of north africa and Middle east for guidance. 
Abbreviation: IDW, inverse distance weighting.
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A very high prevalence represented by red tones 
(≈20%–27%) appears in practically all Great Britain, except 
in the south of the island that presents brownish colors in 
the west and yellow in the center and east consistent with 
an intermediate prevalence. Reddish colors, indicative of a 
very high prevalence, are also shown in the southeast of the 
Scandinavian Peninsula, the Island of Amager (Denmark), 
southeast of Germany, western and southern Poland, Austria, 
,':Q S &23'PHDQSUHYDOHQFH

Figure 2 COPD mean prevalence in europe.
Note: The IDW interpolation map shows the prevalence values of COPD at the points of origin of the patients, both in europe and in some neighboring countries in 
north africa and the Middle east.
Abbreviation: IDW, inverse distance weighting.
,':Q S &23'PHDQSUHYDOHQFH

Figure 3 COPD mean prevalence in europe.
Notes: In this IDW interpolation map, spots and numerical values have been removed to allow a clearer view of the colors with which the different regions appear colored. 
although there is not an exact equivalence between the qualitative data provided by the color scale and the numerical values obtained from published studies, there is an 
approximate correlation between them, which allows interpreting findings of the mapping with reasonable certainty.
Abbreviation: IDW, inverse distance weighting.
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Czech Republic, and Slovakia (these last 2 countries without 
studies and therefore without real numerical values). 
Brown and orange tones (approximately equivalent to a 
range of numerical values between 15% and 20%) appear in 
Iceland, Hungary, large areas of Italy (except the regions of 
Lombardy, Piedmont, Liguria, and Calabria, which appear 
in yellow color), Croatia, Bosnia and Herzegovina, Serbia, 
and Greece, as well as in the province of Adana (southern 
Turkey). Of note, there are no real numerical values for 
the Balkan countries that were colored by means of the 
IDW mapping. 
Most of the remaining regions of Europe are stained 
in yellow and green colors, indicative of an intermediate 
prevalence of ~10%–15%; the Danish peninsula of Jutland, 
most of Sweden, Norway, and northern Finland, the Baltic 
seacoast countries and the Baltic islands of Gotland and 
Aland, Belorussia, most of the lands of Poland, the western 
half of Germany, the coastal regions of Western Europe 
and Great Britain bordering the North Sea and the English 
Channel, Ireland, Portugal, Spain, the Mediterranean major 
islands, Slovenia, Ukraine, Romania, Bulgaria, European 
Russia, Montenegro, Albania, Macedonia, and the Anatolian 
Peninsula are included in this group. Remarkably, many 
of these regions were stained by IDW interpolation in the 
absence of real numerical data. 
Blue areas (indicative of the prevalence of around 
or ,5%) are scarce and isolated; Switzerland, the island of 
Cyprus, some cities of Spain, such as Vigo, Burgos, Cáceres, 
and Seville, scattered areas of the Scandinavian peninsula 
and Finland, and the Erzurum Province of eastern Turkey 
are among them.
Discussion
Existing data on COPD prevalence are in general insufficient 
and irregularly distributed in many regions of Europe, in 
some of which there is a striking scarcity or even an absolute 
lack of epidemiological information about this important 
health issue.
To assess the COPD prevalence throughout the European 
continent and its surrounding islands, an efficient method of 
proven utility, known as IDW multivariate interpolation (or 
spatial analysis), which is usually applied to various disci-
plines concerned with the earth’s surface, such as cartogra-
phy, geography, hydrology, climatology, and agriculture, was 
used in the present study in order to generate a continuous 
map of COPD prevalence. 
Basically, IDW interpolation uses data points with known 
values to estimate other values at unknown locations, in order 
to create a raster surface consisting of an array of cells (pixels) 
arranged in rows and columns (or a grid) in which each cell 
contains a value representing some prevalence information, 
finally covering a whole area. The IDW method is based on 
the assumption that the attribute value of an unsampled point 
is the weighted average of known values within the 4 nearest 
data points. IDW assumes that each measured point has a 
local influence that diminishes with distance, weighting the 
points closer to the prediction location greater than those 
located farther away, which means that weights are inversely 
related to the distances between the sampled locations and 
the predicted ones.7 
The IDW interpolation is a simple and intuitive method, 
easy to handle and interpret, relatively fast for calculations, 
and easy to compute, which also has the advantage of allow-
ing to easily renewing the database, with a flexibility of the 
inclusion of studies newly identified, that are more recent, 
or with a better study design. Similar flexibility applies to 
the exclusion of others of less scientific quality to automati-
cally reconstructing new, updated maps. In addition, IDW 
has a mathematical precision that makes it always exact, 
but this advantage can be a disadvantage if the actual data 
were erroneous or inaccurate. Since it works automatically 
creating new points from others supposedly accurate, it is 
crucial to introduce reliable data; otherwise the final results 
will also be inaccurate or erroneous. 
For the present study, the numerical data of prevalence 
rates were obtained with the best available evidence in 
publicly accessible scientific databases, and only surveys 
constituted by patients of at least $40 years of age and a 
confirmed diagnosis of COPD with spirometry were selected 
for the analysis. 
Limitations
However, the authors of the present study are aware that the 
analysis may have some limitations due to a number of con-
founding factors frequently associated with cross-sectional 
studies, and sometimes these confounding variables could 
have led to spurious associations. For example, the sampling 
approach varied from study to study or even among sites in 
the same study. In addition, the size of the samples was highly 
variable, with significant differences between regions, and 
some of them were not proportional to the general population 
of the studied region. Remarkably, the lack or scarcity of data 
in extensive regions of Europe makes the scientific hypotheses 
from which some conclusions were drawn less reliable. 
There are also some (though not statistically signifi-
cant) differences in the age distribution between regions of 
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Europe and even within the same region of the same country, 
and since in spirometry-based studies the prevalence of 
COPD increases with age, the lack of homogeneity in this 
variable may be the reason for some of the erratic values. 
On the other hand, when modeling relative risks or ORs 
from data obtained from a given population, results may not 
be applicable to populations with different levels of expo-
sure, as the relations may not be linear across all exposure 
levels. Regrettably, in our study, there was no proportionality 
between the number of urban and rural cohorts, and thus, stud-
ies performed in populations with high levels of smoking or 
occupational air pollutants exposure may not be generalizable 
to those of populations with lower levels of exposure. 
Another limitation may be related to the differences in 
case definitions. The definition based on post-BD FEV
1
/
FVC ,0.70 was used in the large majority (80%) of studies, 
but this still does not address all possible sources of varia-
tion in case definition, since this fixed ratio criterion may 
potentially overdiagnose COPD in the elderly and it may 
underdiagnose COPD in younger patients. Besides, a number 
of technical issues could have affected the estimates, such 
as the quality of the commercial models of the spirometers 
used, the level of training of the operators, and the process of 
collection and storage of spirometry measurements.2–5 
Finally, an intrinsic limitation of GIS is that geographic 
proximity does not take into account borders, which often 
within Europe mirror a different language or dialect. Common 
language is a well-established factor for unevenly distribut-
ing genes, related to or not to health, and many other social 
determinants.78
Nevertheless, in spite of all these criticisms, it should 
be emphasized that GIS unquestionably offers a useful new 
tool in epidemiology, which makes it ever easier to connect 
spatially referenced physical and social phenomena to popu-
lation patterns of health, disease, and well-being. 
Therefore, in our opinion, the easy-to-interpret and eye-
catching impacting results of this technique may contribute 
to enhancing public health surveillance as well as delineating 
the prevalence of COPD in Europe and in other countries; 
to increase the number of doctors who treat this type of 
patients and the health authorities and national governments’ 
interest in strengthening regulations to address occupational 
and environmental risk factors, regulate tobacco use, and 
improve public awareness; to all together increase the rate 
of diagnoses and to implement the application of preven-
tive and therapeutic measures to avoid potential side effects 
and unnecessary costs; and to reduce the high global COPD 
burden in coming years.
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